Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stock Now Rated “Hold” by Wall Street Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have earned an average rating of “Hold” from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $13.20.

A number of equities research analysts have recently weighed in on XERS shares. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. Barclays raised their target price on Xeris Biopharma from $12.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 6th. Leerink Partners lifted their price target on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. Finally, Wall Street Zen upgraded Xeris Biopharma from a “hold” rating to a “buy” rating in a research note on Saturday, September 19th.

Xeris Biopharma Price Performance

Shares of XERS opened at $11.13 on Friday. The company has a 50 day moving average of $8.99 and a two-hundred day moving average of $7.72. The company has a quick ratio of 1.02, a current ratio of 1.45 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $11.41. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -101.18 and a beta of 0.53.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. As a group, analysts predict that Xeris Biopharma will post 0.07 earnings per share for the current fiscal year.

Insider Transactions at Xeris Biopharma

In related news, insider Kevin McCulloch sold 25,000 shares of Xeris Biopharma stock in a transaction dated Monday, September 28th. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. Following the completion of the sale, the insider owned 1,614,208 shares of the company’s stock, valued at $16,142,080. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,666 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $9.41, for a total transaction of $156,827.06. Following the sale, the insider owned 1,111,130 shares of the company’s stock, valued at approximately $10,455,733.30. The trade was a 1.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 134,998 shares of company stock worth $1,202,666 over the last three months. 4.35% of the stock is currently owned by insiders.

Institutional Trading of Xeris Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in XERS. GK Wealth Management LLC acquired a new position in Xeris Biopharma during the third quarter worth $32,000. Vilga Financial Planning LLC purchased a new stake in shares of Xeris Biopharma during the 3rd quarter valued at approximately $10,134,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Xeris Biopharma during the 2nd quarter valued at approximately $74,000. Allworth Financial LP lifted its holdings in Xeris Biopharma by 86.4% in the second quarter. Allworth Financial LP now owns 4,315 shares of the company’s stock valued at $34,000 after acquiring an additional 2,000 shares during the last quarter. Finally, Allianz Asset Management GmbH acquired a new position in Xeris Biopharma in the second quarter valued at approximately $314,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.